Alaunos Therapeutics, Inc. Segments Disclosure
15. Segment Information
The CODM for the Company is the (the "CEO"). The Company’s CEO reviews operating results on an aggregate basis and manages the Company’s operations as a whole for the purpose of evaluating financial performance and allocating resources. This decision-making process reflects the way in which financial information is regularly reviewed and used by the CODM to evaluate performance, set
operational targets, forecast future financial results, and allocate resources. Accordingly, the Company has determined that it has a single reportable and operating segment related to biopharmaceutical research and development.
The Company’s CODM assesses financial performance and allocates resources based on consolidated operating results which are also reported on the consolidated statements of operations. The measure of segment assets is reported on the balance sheet as total consolidated assets. The CODM utilizes consolidated operating results by comparing actual results against budgeted amounts. As part of this process, consolidated net loss is a critical performance measure used to evaluate the Company’s operating performance and guide strategic decisions and resource allocations, including additional investments in research and development. The table below provides information about the Company’s revenue, significant segment expenses and other segment expenses.
The table below provides information about the Company’s revenue, significant segment expenses and other segment expenses.
|
|
For the Years Ended December 31, |
|
|
|||||||
($ in thousands) |
|
2024 |
|
|
2023 |
|
|
||||
Revenues |
|
$ |
10 |
|
|
$ |
5 |
|
|
||
Less segment expenses: |
|
|
|
|
|
|
|
|
|
||
Research and development |
|
|
340 |
|
|
|
|
16,279 |
|
|
|
General and administrative |
|
|
|
4,436 |
|
|
|
|
12,219 |
|
|
Gain on lease modification |
|
|
- |
|
|
|
(298) |
|
|
||
Restructuring costs |
|
|
- |
|
|
|
|
1,269 |
|
|
|
Property and equipment and right-of-use asset impairment |
|
|
- |
|
|
|
|
4,803 |
|
|
|
Total operating and segment expense |
|
|
|
4,776 |
|
|
|
|
34,272 |
|
|
Plus: |
|
|
|
|
|
|
|
|
|
||
Interest expense |
|
|
- |
|
|
|
(1,921) |
|
|
||
Other income, net |
|
|
133 |
|
|
|
|
1,048 |
|
|
|
Segment Net loss |
|
$ |
(4,633 |
|
) |
$ |
(35,140) |
|
|
||
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.